Cost pressure of the new hepatitis C drugs in Canada = Pressions exercées sur les coûts des nouveaux médicaments contre l’hépatite C au Canada. : H82-25/2016-PDF

"The pricing, utilization and cost related to the direct-acting antivirals (DAAs) for the treatment of hepatitis C has become a critical issue for public plans, private insurers and patients. This study provides insight into the use, pricing and cost of DAAs in Canada and internationally in 2015, along with a retrospective look at the recent trends. The international analysis focuses on the PMPRB7 countries: France, Germany, Italy, Sweden, Switzerland, the United Kingdom (UK) and the United States (US). Results for the Canadian market are reported at the national level, as well as for the private and public market segments."

Lien permanent pour cette publication :
publications.gc.ca/pub?id=9.833934&sl=1

• Format MARC XML
• Format MARC HTML

Demander des formats alternatifs